Dosimetry Prediction for Clinical Translation of $^{64}$Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression

Arutselvan Natarajan¹, Chirag B. Patel¹, Frezghi Habte¹ & Sanjiv S. Gambhir¹,²,³

The immune checkpoint programmed death 1 receptor (PD-1) expressed on some tumor-infiltrating lymphocytes, and its ligand (PD-L1) expressed on tumor cells, enable cancers to evade the immune system. Blocking PD-1 with the monoclonal antibody pembrolizumab is a promising immunotherapy strategy. Thus, noninvasively quantifying the presence of PD-1 expression in the tumor microenvironment prior to initiation of immune checkpoint blockade may identify the patients likely to respond to therapy. We have developed a $^{64}$Cu-pembrolizumab radiotracer and evaluated human dosimetry. The tracer was utilized to image hPD-1 levels in two subcutaneous mouse models: (a) 293 T/hPD-1 cells xenografted into NOD-scid IL-2Rγnull mice (NSG/293 T/hPD-1) and (b) human peripheral blood mononuclear cells engrafted into NSG bearing A375 human melanoma tumors (hNSG/A375). In each mouse model two cohorts were evaluated (hPD-1 blockade with pembrolizumab [blk] and non-blocked [nblk]), for a total of four groups (n = 3–5/group). The xenograft-to-muscle ratio in the NSG/293 T/hPD-1 model at 24 h was significantly increased in the nblk group (7.0 ± 0.5) compared to the blk group (3.4 ± 0.9), p = 0.01. The radiotracer dosimetry evaluation (PET/CT ROI-based and ex vivo) in the hNSG/A375 model revealed the highest radiation burden to the liver. In summary, we validated the $^{64}$Cu-pembrolizumab tracer’s specific hPD-1 receptor targeting and predicted human dosimetry.

The use of immune checkpoint (IC) blockade strategies, e.g. against programmed death-1 receptor (PD-1), PD-1’s ligand (PD-L1), and cytotoxic lymphocyte antigen-4 (CTLA4) is expanding in cancer immunotherapy¹. Many preclinical studies have demonstrated that blockade of these ICs, particularly PD-1 and PD-L1, with monoclonal antibodies enhances tumor cell-specific T-cell activation, cytokine production, anti-tumor effector mechanisms, and clearance of tumor cells by the immune system²–⁴. These studies have led to accelerated FDA approval of several antibodies as a second-line therapy in advanced melanoma and non-small cell lung cancer (NSCLC).

Pre-clinical and clinical studies have shown that T-cell immune surveillance is controlled by the PD-1 pathway, which represents a major immune checkpoint that could be targeted for therapy⁵. PD-1 inhibition was tested in a clinical study of a variety of solid tumor types, and promising survival benefits were noted, including in melanoma and NSCLC⁶. Further, it has been suggested that PD-1 regulates tumor-specific T-cell expansion of tumor-infiltrating lymphocytes (TILs) in patients with melanoma⁷. Pembrolizumab is a high affinity (Kd = 29 pM) IgG4-κ humanized monoclonal antibody that is created by grafting the variable binding portion of a mouse anti-human PD-1 antibody onto a human isotype framework containing a stabilizing S228P mutation in the Fc region (see Fig. 1a).

Safety, tolerability, pharmacokinetics, and immunogenicity of pembrolizumab have been investigated in patients with advanced solid tumors including advanced melanoma and NSCLC⁸–⁹. In a cohort of 135 advanced melanoma patients undergoing anti-hPD-1 therapy, a durable response rate of greater than 50% was observed⁸,⁹. The ligands for PD-1 (PD-L1 and PD-L2) are constitutively expressed or can be induced in various tumors including melanoma¹⁰–¹¹. The high expression of PD-L1 (and to a lesser extent, PD-L2) on tumor cells is correlated with poor prognosis in various cancer types, especially in NSCLC¹²–¹⁴.

¹Department of Radiology, School of Medicine, Stanford University, Stanford, CA, United States. ²Department of Bioengineering, Stanford University, Stanford, CA, United States. ³Materials Science & Engineering, Stanford University, Stanford, CA, United States. Correspondence and requests for materials should be addressed to S.S.G. (email: sgambhir@stanford.edu)
hPD-1 receptor imaging could provide a non-invasive method to track and quantify the number of hPD-1-expressing TILs in the tumor microenvironment. In this regard, use of an immunoPET tracer may help to screen for cancer patients likely to respond to anti-PD-1 immunotherapy. In the present study, we have evaluated an anti-hPD-1 immunoPET tracer (64Cu-pembrolizumab) in two mouse models bearing human-derived cell lines, measured tracer residence time in clearance organs, and predicted human equivalent dosimetry.

**Results**

**Synthesis and Quality Control of the immunoPET Tracer.** HPLC-purified pembrolizumab was conjugated to DOTA-NHS (Do) with lysine groups of pembrolizumab (10:1 molar ratio) at pH 8.0, which yielded Do-pembrolizumab of 1–2 chelates per antibody (c/a), which was confirmed by MALDI-TOF mass spectrometry (Supplementary Fig. S1). This DOTA-conjugated antibody was further purified by SEC-2000-HPLC column and radiolabeling of 64Cu with Do-pembrolizumab yielded >70% 64Cu-pembrolizumab and provided >99% purity by SEC-2000-HPLC with 1.5 × 10^4 Ci/mmol specific activity (Fig. 1b and Supplementary Fig. S2).

**ImmunoPET Images of NSG/293 T/hPD-1 Mouse Xenograft Model.** Because the athymic NSG/293 T/hPD-1 mice lacked intrinsic T cells and hPD-1, this model was chosen to avoid cross-reactivity with murine PD-1 during PET imaging. Figure 2 displays representative sagittal immunoPET images of NSG/293 T/hPD-1 mice (at 4, 24 and 48 h post-injection [p.i.]) bearing the hPD-1-expressing 293 T xenograft in the shoulder. These immunoPET images demonstrate that the 64Cu-pembrolizumab tracer specifically binds to hPD-1-expressing 293 T xenograft in the nblk group (Fig. 2b) compared to the blk group (Fig. 2a). The tracer clearance temporal profiles in the heart, liver, and spleen were quantified (ROI: mean ± SD % ID/g) and plotted against various time points (1–48 h) for each of the blk and nblk groups, and are presented in Fig. 2c and d, respectively. At 48 h, the heart/liver/spleen uptake in the blk and nblk groups was 7.9 ± 0.5/5.6 ± 0.4/5.5 ± 0.2 and 7.1 ± 0.8/7.3 ± 0.2/13.0 ± 0.8% ID/g, respectively.

**Tracer Uptake in Tumor and Clearance Organs of the NSG/293 T/hPD-1 Xenograft Mice and Biodistribution Study.** Figure 3a shows the tracer uptake in the xenograft in the blk and nblk groups of the NSG/293 T/hPD-1 mice at 4, 24 and 48 h p.i (mean ± SD % ID/g). Tracer uptake in the blk group was significantly less than that in the nblk group at 4, 24, and 48 h, 1.3 ± 0.3 vs. 2.9 ± 0.3 (p = 0.001), 3.2 ± 0.1 vs. 8.2 ± 0.3 (p = 0.001), and 5.5 ± 0.1 vs. 14.8 ± 1.2 (p = 0.005), respectively. This represents a 100–200% increase in xenograft tracer uptake in the nblk group compared to the blk group for all time points shown. Figure 3b shows that the xenograft-to-muscle ratio (XMR) at 24 and 48 h p.i. was significantly greater in the nblk group compared to the blk group, 7.0 ± 0.7 vs. 3.4 ± 0.9 (p = 0.002) and 15.5 ± 1.4 vs. 4.7 ± 0.6 (p < 0.001), respectively. Figure 3c shows the biodistribution study results of the tracer after the 48 h microPET-CT scan. The xenograft tracer uptake (mean ± SD % ID/g) was significantly greater in the nblk group (17.0 ± 1.6) compared to the blk group (5.7 ± 1.3), p = 0.001. The XMR based on ex vivo organ cpm’s was significantly greater in the nblk group (16.2 ± 2.1) compared to the blk group (5.1 ± 1.3), p = 0.003. The tracer uptake in spleen in the NSG/293 T/hPD-1 mice was comparable to that in the xenograft, and was significantly greater in the nblk group (17.5 ± 1.6% ID/g) compared to the blk group (5.7 ± 1.3% ID/g), p = 0.001 (Fig. 3c).

**H&E and Immunofluorescence of Xenograft in NSG/293 T/hPD-1 Mice.** Representative images of immunofluorescence and H&E sections of the xenograft and contralateral normal tissue from nblk and blk NSG/293 T/hPD-1 mice are shown in Fig. 4a and b, respectively. H&E (last column of both subfigures) revealed the mostly eosin-staining xenograft tissue compared to the mostly hematoyxlin-staining contralateral normal tissue (Fig. 4a,b). From left to right, Fig. 4a,b show immunofluorescence for DAPI (nuclear stain, blue), human PD-1 (a marker for the human 293 T/hPD-1 xenograft, green), and human IgG (a marker for pembrolizumab, red), and the merge of the three prior images. Immunofluorescence for human PD-1 demonstrated diffuse staining in the xenograft of nblk mice compared to absent staining in the blk mice, confirming the PD-1-blocking effect of pembrolizumab.
pembrolizumab. In the contralateral normal tissue, nblk mice had minimal/autofluorescence staining compared to absent staining in the blk mice. Immunofluorescence for human IgG demonstrated minimal/autofluorescence staining in the xenograft of nblk mice compared to marked staining in the blk mice, confirming the presence of pembrolizumab in the blk group. In the contralateral normal tissue, nblk mice had absent staining whereas blk mice had moderate staining, again confirming the presence of pembrolizumab in the latter group.

**64Cu-pembrolizumab immunoPET Imaging of Humanized hNSG/A375 Melanoma Mouse Model.** Figure 5a shows representative axial and coronal immunoPET images (at 24 h and 48 h p.i. of the tracer) of humanized hNSG/A375 mice bearing the melanoma in the left shoulder, with important organs (heart, liver, and spleen) delineated on the representative microCT and microPET-CT co-registered images. These immunoPET images clearly show that the 64Cu-pembrolizumab tracer specifically binds to the hPD-1 protein expressed on a subpopulation of human TILs homing to the tumor microenvironment. The marked difference in PET signals (non-decay corrected) between the tumor and background (i.e. muscle) is apparent in the 24 and 48 h p.i. scans. Compared to the nblk mice that did not receive non-radioactive pembrolizumab prior to the scan, the blk mice had significantly decreased tracer tumor uptake at both 24 h (1.8 ± 0.2 vs. 1.4 ± 0.2% ID/g, p = 0.04) and 48 h (0.44 ± 0.01 vs. 0.37 ± 0.01% ID/g, p < 0.001).

Figure 5b,c display the clearance profile of the tracer (non-decay corrected) from heart, liver, and spleen in the blk and nblk groups, respectively. ROI measurement of immunoPET indicated that the PET signal obtained from the spleen and tumor was high due to the hPD-1-expressing lymphocytes present in these sites. For example, at 24 h p.i., the tracer residence (% ID/g ± SD) in the hNSG/A375 mice heart/liver/spleen in the nblk and blk groups was 1.62 ± 0.19/1.10 ± 0.09/1.18 ± 0.10 and 1.16 ± 0.21/0.88 ± 0.05/0.85 ± 0.07 (p = 0.02, p = 0.01, and p = 0.001), respectively. By 48 h p.i., most of the organs in each group had less than 0.3% ID/g of the immunoPET tracer remaining. Supplementary Video S3 is a three-dimensional microPET-CT visualization of hPD-1-expressing tumor-infiltrating lymphocytes in the tumor microenvironment of hNSG/A375 melanoma-bearing mice, at 24 hours post-injection of 64Cu-pembrolizumab.

**Dosimetry.** Dosimetry (ROI, and ex vivo biodistribution) was computed from the biodistribution data of the hNSG/A375 mouse model. The absorbed radiation dose estimates corresponding to human organs for the administration of 64Cu-pembrolizumab are summarized in Table 1. The area under the curve of each organ's activity was computed using the trapezoidal model in Prism software (La Jolla, CA), for both PET/CT-based and ex vivo biodistribution data. The PET/CT ROI method revealed that the organs with the highest radiation burden (μSv/MBq) in the blk and nblk groups were the liver (35.2 ± 1.2 and 37.6 ± 2.2, respectively) and heart (17.1 ± 1.5 and
17.8 ± 3.5, respectively). The ex vivo immunoPET biodistribution profiles at 1, 12, 24, and 48 hours post-injection in the hNSG/A375 mouse model are shown in Supplementary Fig. S4. The tracer uptake in each tissue was computed as mean ± standard deviation % ID/g (non-decay-corrected). This ex vivo method revealed that the organs with the highest radiation burden (μSv/MBq) in the blk and nblk groups were the liver (32.9 ± 3.6 and 34.2 ± 3.4, respectively) and red marrow (18.6 ± 0.9 and 24.1 ± 0.3, respectively). Human equivalent doses (μSv/MBq) were predicted for the blk and nblk groups, and revealed the liver to be the dose-limiting organ in both groups. The dosimetry evaluation from the PET/CT ROI-based and ex vivo biodistribution approaches resulted in comparable human equivalent liver doses ranging from 33–38 μSv/MBq. In the blk and nblk groups, the effective dose (μSv/MBq) was 4.3 ± 0.03 and 4.5 ± 0.3, respectively, and the effective dose equivalent value (μSv/MBq) was 2.4 ± 0.1 and 2.5 ± 0.3, respectively. The annual dosimetry of an adult human male receiving pembrolizumab prior to 64Cu-pembrolizumab was found to be 1.42 ± 0.05 GBq whereas it would be 1.33 ± 0.08 GBq in patients receiving only the tracer.

Discussion

We previously presented the development of a 64Cu-pembrolizumab immunoPET tracer, including synthesis, serum stability, and immunoreactivity18. In the current report, we have validated the 64Cu-pembrolizumab tracer in two different mouse models, one bearing a hPD-1-expressing 293 T stable cell line xenograft (NSG/293 T/hPD-1) and the other bearing a human A375 tumor that does not express hPD-1 but in which some infiltrating TILs do express hPD-1 (hNSG/A375). The tracer quality was of high immunoreactivity and we were able to visualize the PET signal clearly from hPD-1-expressing cells in both mouse models. Moreover, the PET signal in the hPD-1-expressing TILs present in the non-hPD-1-expressing melanoma contrasted well against clearance organs and background tissues.

The immunohistochemistry (IHC)-based assay determination for hPD-L1 expression to predict response to anti-hPD-1 therapy varies among cancer types. For example, in NSCLC, there is a directly proportional correlation between hPD-L1 expression and response to anti-hPD-1 therapy. However, this hPD-L1/treatment response correlation is not present in melanoma19. Given the adaptive nature of the immune response exerted by tumor cells over time, it is possible that the hPD-L1 expression in the tissue sampled for IHC could increase over the course of the disease20,21. We have instead focused on imaging hPD-1 expression directly because it indicates
the presence of hPD-1-expressing TILs in the tumor microenvironment. This approach raises the possibility for hPD-1 immunoPET to predict responders to anti-hPD-1 therapy, e.g. immune checkpoint blockade with pembrolizumab or nivolumab. Furthermore, once an appropriately selected patient is started on a hPD-1 blocker, immunoPET could also be used as a noninvasive companion diagnostic to assess treatment response. One caveat of this approach is the controversial role of hPD-1 as both an activation marker, and in the setting of some solid tumors with high hPD-L1 expression, an exhaustion marker, of TILs 22.

England and colleagues previously reported on the pharmacokinetics and biodistribution of \(^{89}\text{Zr-Df-pembrolizumab}\) in healthy mice and rats, and in severe combined immunodeficient NSG mice engrafted with hPBMCs 23. However, animal models bearing human xenografts or tumor cells were not studied using \(^{89}\text{Zr-Df-pembrolizumab}\) tracer. In the current study, we tested the \(^{64}\text{Cu-pembrolizumab}\) immunoPET tracer in two different mouse models bearing human-derived cells. The 293 T/hPD-1 mouse model served as a positive control because of this non-cancer cell line's stable expression of hPD-1, and the hNSG/A375 melanoma model served as a representative cancer model in which hPD-1-expressing TILs home to the tumor microenvironment. Furthermore, we studied two groups within each mouse model, pre-blocking hPD-1 with non-radioactive pembrolizumab (blk) and not pre-blocking (nblk), in order to demonstrate the specificity and increased immunoPET tracer tumor (or xenograft) targeting in the nblk group. Although both models show clear immunoPET contrast with respect to tumor (or xenograft) uptake compared to background tissue, the tumor (or xenograft) image patterns are very different. For example, tracer uptake in the NSG/293 T/hPD-1 model (Fig. 2a) is more uniform due to stable expression of the hPD-1 receptor in the xenografted cells. However, in hNSG/A375 tumor mouse model, the tracer uptake is heterogeneous (Fig. 5a), likely illustrating the variable infiltration of hPD-1-expressing TILs that is dependent on the melanoma microenvironment, e.g. the distribution of permeable blood vessels. Further, the hPD-1 signal from these TILs decreases as they likely become exhausted and their hPD-1 receptor relocates to macrophages via Fc-RIIb receptor binding22.

We predicted the safe human dose that can be injected annually into a patient without surpassing the FDA-allowed dose limits. We performed dosimetry in blocking and non-blocking groups within the hNSG/A375 melanoma mice because this model mimics the situation in which hPD1-expressing TILs invade the tumor. In clinical practice, it is common to administer a non-radioactive antibody to pre-block the spleen from the radiotracer. For example, non-radioactive ibritumomab, a monoclonal antibody targeting CD20, was administered prior to \(^{90}\text{Y-ibritumomab tiuxetan radioimmunotherapy}\) in relapsed B-cell non-Hodgkin's lymphoma 24. This reduces immunoPET tracer splenic accumulation during therapy, allowing more tracer molecules to be available to effectively bind the target site. Likewise, we administered a sufficient pre-dose of non-radioactive pembrolizumab to block off-target hPD-1 binding in multiple organs, including in the tumor, to distinguish the specific binding of the \(^{64}\text{Cu-pembrolizumab}\) tracer.

The annual radiation dose limit to the whole body, gonads, and active blood-forming organs, and lens of the eye is 50 mSv; and for a single study is 30 mSv 25. The dose absorbed by all other organs should not exceed 150 mSv annually and 50 mSv for a single study 25. With respect to \(^{64}\text{Cu-pembrolizumab}\) tracer, the liver was the dose-limiting organ in both the blk and nblk groups. This is possibly because of its interaction with hepatic Kupffer cells 25. Also, a small unstable fraction of the \(^{64}\text{Cu}\) that leaks out from the DOTA chelate may undergo...
trans-chelation in the liver; however, because the 12.7-hour half-life of the radioisotope is far shorter than the 3–4 week half-life of its bound antibody, the concern for prolonged hepatic radiotoxicity is mitigated.

In the case of 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]-FDG), the limiting dose in adults is 0.13 mSv/MBq, or 384 MBq per scan. In contrast, the 64Cu-pembrolizumab scan dose would be much less, such that the predicted human dose should lower the absorbed dose in critical organs. In a future translational application of this tracer to the clinic, patients would first receive non-radioactive pembrolizumab, followed by 64Cu-pembrolizumab. In such a study, we would plan to inject 185 ± 10 MBq of tracer per scan, which would allow for multiple immuno-PET scans per year without exceeding the annual dose limit.

Previous anti-hPD-1 immunotherapy studies in NSG mouse models and human have demonstrated the infiltration of hPD-1-expressing TILs into the tumor and other organs. For example, England et al. performed hCD3 and hPD-1 immunohistochemistry to demonstrate infiltration of TILs into the salivary glands of NSG mice engrafted with human PBMCs but not in NSG mice bearing tumors. Using immunofluorescence microscopy, we have demonstrated the pembrolizumab-specific uptake in the 293 T/hPD-1 xenografted mouse model in the nblk compared to the blk group. These immunofluorescence results provide qualitative confirmation of the immuno-PET findings that pre-blocking hPD-1 with non-radioactive pembrolizumab (blk) minimizes off-target binding in the xenografted tissue itself.

The results of this study should be interpreted in the context of a limitation. Although we used the 293 T/hPD-1 xenograft model as a positive control to validate our immunoPET tracer with blk and nblk subgroups,
we did not use a truly negative control (i.e. a non-tumor cell line that also does not express hPD-1). Overall, the 64Cu-pembrolizumab immunoPET tracer is well-suited for imaging hPD-1-expressing TILs because of the decay half-life of 64Cu compared to the biological half-life of the antibody (12.7 h vs. 3–4 weeks, respectively), as well as the specific binding demonstrated by the blk and nblk groups. Based on the findings in the current study and those from other groups, we anticipate that this tracer has the potential to detect even small quantities of hPD-1-expressing TILs in the tumor microenvironment, which may otherwise be difficult to directly measure. Moreover, the 64Cu-pembrolizumab tracer is more specific with respect to imaging hPD-1-expressing TILs when compared to a 64Cu-pembrolizumab tracer. The annual human dose of this tracer is well within the FDA-accepted limits.

**Conclusions**

Using two mouse models in which the engrafted tissue either expressed hPD-1 or attracted infiltrating hPD-1-expressing lymphocytes, we have shown that the 64Cu-pembrolizumab tracer has specific targeting. This is the first report of human dosimetry of the 64Cu-pembrolizumab tracer. The liver was found to be the dose-limiting organ using PET/CT ROI-based and ex vivo dosimetry across both mouse groups. The predicted annual human dose of this tracer is well within the FDA-accepted limits.

**Materials and Methods**

**Antibodies, Radioisotope, and Reagents.** Pembrolizumab (25 mg/mL, Keytruda®; Merck & Co., Kenilworth, NJ), a humanized monoclonal immunoglobulin IgG4 antibody directed against human PD-1 (hPD-1), was purchased from Stanford University Hospital Pharmacy (Stanford, CA). The radioisotope chelator N-succinimidyl-DOTA (NHS-DOTA) was purchased from Macrocyclics (Dallas, TX). 64Cu CuCl₂ was purchased

---

| Organ         | Total Dose (μSv/MBq) | PET/CT Images | Ex vivo biodistribution |
|---------------|----------------------|---------------|-------------------------|
|               |                      | Blk | Nblk | Blk | Nblk |
| Adrenal glands| 1.89 ± 0.028 | 2.005 ± 0.12 | 2.856 ± 0.12 | 3.38 ± 0.319 |
| Brain         | 0.072 ± 0.002 | 0.075 ± 0.001 | 0.422 ± 0.02 | 0.615 ± 0.041 |
| Breasts       | 0.502 ± 0.002 | 0.53 ± 0.038 | 0.867 ± 0.036 | 1.076 ± 0.11 |
| Gallbladder   | 3.24 ± 0.084 | 3.45 ± 0.197 | 3.71 ± 0.247 | 4.14 ± 0.438 |
| LLI wall      | 0.388 ± 0.01 | 0.405 ± 0.009 | 1.173 ± 0.06 | 1.526 ± 0.127 |
| Small intestine | 0.694 ± 0.003 | 0.733 ± 0.031 | 6.14 ± 0.704 | 6.88 ± 1.462 |
| Stomach wall  | 0.932 ± 0.003 | 0.977 ± 0.046 | 3.256 ± 0.669 | 3.826 ± 0.967 |
| ULI wall      | 0.928 ± 0.011 | 0.985 ± 0.049 | 5.03 ± 1.18 | 7.286 ± 1.992 |
| Heart wall    | 17.05 ± 1.484 | 17.75 ± 3.464 | 6.51 ± 0.4 | 7.606 ± 1.377 |
| Kidneys       | 1.335 ± 0.021 | 1.41 ± 0.07 | 13.166 ± 0.602 | 17.866 ± 4.834 |
| Liver         | 35.15 ± 1.202 | 37.55 ± 2.192 | 32.866 ± 3.617 | 34.166 ± 3.35 |
| Lungs         | 1.045 ± 0.007 | 1.105 ± 0.077 | 10.383 ± 0.748 | 12.036 ± 1.908 |
| Muscle        | 1.825 ± 0.049 | 1.905 ± 0.049 | 2.12 ± 0.156 | 2.59 ± 0.33 |
| Ovaries       | 0.502 ± 0.008 | 0.526 ± 0.015 | 1.413 ± 0.075 | 1.81 ± 0.181 |
| Pancreas      | 1.735 ± 0.021 | 1.83 ± 0.098 | 6.123 ± 0.751 | 8.36 ± 2.314 |
| Red marrow    | 0.621 ± 0.004 | 0.655 ± 0.032 | 18.566 ± 0.85 | 24.133 ± 0.251 |
| Osteogenic cells | 0.5 ± 0.003 | 0.526 ± 0.023 | 10.373 ± 0.44 | 13.6 ± 1.6 |
| Skin          | 0.339 ± 0.002 | 0.357 ± 0.015 | 0.594 ± 0.024 | 0.8 ± 0.114 |
| Spleen        | 6.705 ± 0.289 | 6.075 ± 0.572 | 13.5 ± 3.377 | 18.766 ± 7.479 |
| Testes        | 0.273 ± 0.009 | 0.284 ± 0.004 | 0.464 ± 0.034 | 0.638 ± 0.067 |
| Thymus        | 0.704 ± 0.021 | 0.739 ± 0.062 | 1.173 ± 0.049 | 1.46 ± 0.165 |
| Thyroid       | 0.345 ± 0.01 | 0.36 ± 0.01 | 0.691 ± 0.038 | 0.917 ± 0.08 |
| Urinary Bladder Wall | 0.4 ± 0.01 | 0.418 ± 0.009 | 0.784 ± 0.047 | 1.037 ± 0.101 |
| Uterus        | 0.473 ± 0.008 | 0.495 ± 0.014 | 1.16 ± 0.059 | 1.523 ± 0.191 |
| Total Body    | 2.015 ± 0.007 | 2.125 ± 0.106 | 3.08 ± 0.695 | 3.693 ± 0.332 |
| Effective Dose Equivalent | 4.27 ± 0.028 | 4.46 ± 0.353 | 8.65 ± 0.055 | 10.653 ± 1.308 |
| Effective Dose | 2.37 ± 0.056 | 2.515 ± 0.134 | 6.413 ± 0.085 | 7.69 ± 0.624 |
| LLI: Lower large intestine, ULI: Upper large intestine |
from the University of Wisconsin (Madison, WI). All other experimental reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.

**Cell Lines and Instruments.** The hPD-1 stably-expressing 293 T human embryonic kidney cell line was purchased from Crown Biotech (San Jose, CA). These cells were incubated with 3 ng/mL of puromycin in Dulbecco’s modified Eagle medium (DMEM) for epidermal growth factor receptor (EGFR)-positive cell selection. To confirm hPD-1 expression, fluorescence-activated cell sorting (FACS) was performed. For tumor implantations in mice, the A-375 melanoma cell line was purchased from American Type Culture Collection (ATCC® number CRL-1619, Manassas, VA) and maintained in DMEM. DMEM was supplemented with 10% fetal calf serum, 2 mmol/L glutamine, 100 units/mL penicillin, 100 μg streptomycin, and 0.25 μg/mL fungizone. All media and additives were obtained from Invitrogen Corporation (Carlsbad, CA). High-performance liquid chromatography (HPLC) was performed on an HPLC-Ultimate 3000 (Thermo Scientific, Waltham, MA) with a size-exclusion chromatography (SEC)2000 LC column (300 × 7.8 mm) with a 5-μm, hydrophilic-bonded silica support of 400 Å pore size (Phenomenex, Torrance, CA) with an ultraviolet detector and an online radioactivity detector. An instant thin-layer chromatography strip (Biodex Medical Systems, Shirley, NY) with saline as mobile phase was employed as an additional quality test for purity of the tracer.

**Synthesis of DOTA-pembrolizumab and ⁶⁴Cu-DOTA-pembrolizumab.** Pembrolizumab antibody was purified by Phenomenex SEC. 2000 HPLC with phosphate buffer solution (PBS, pH 8.0) and buffer exchanged with 1 M HEPES and 0.1 M Na₂CO₃ (pH 8.5 ± 0.5) and concentrated to ∼5 mg/mL using a Vivaspin 30-kDa centrifugal filter (Thermo Fisher Scientific, Waltham, MA). Coupling conditions and detailed experimental procedures of DOTA-pembrolizumab have been reported. The number of chelators (c) coupled per antibody (a) i.e., c/a, was estimated with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) by comparison of unmodified pembrolizumab to DOTA-pembrolizumab.

**In vitro Live Cell-Binding Assay of DOTAPembrolizumab.** DOTA-pembrolizumab was compared with unmodified pembrolizumab in hPD-1-expressing 293 T cells, and analyzed by FACS. Briefly, pembrolizumab and DOTA-pembrolizumab were diluted to 1 nM solution in FACS buffer (Dulbecco’s PBS). Staining was performed in 96-well microtiter plates (V-bottom). The experimental procedure is described in detail in the Supplementary section. Data were analyzed by FlowJo FACS analysis software version 10.1 (Tree Star, Ashland, OR).

**Synthesis of ⁶⁴Cu-pembrolizumab.** A reaction vial containing 0.5 mg of DOTA-pembrolizumab (100 μL) and ⁶⁴CuCl₂ isotope (260–270 MBq; 750 ± 0.5) and incubated at 37°C. Ethylenediaminetetraacetic acid (EDTA, 0.1 M, pH 8.0), was added to the reaction vial after 60 min, to achieve a final concentration of 10 mM for 15 min to scavenge unchelated ⁶⁴Cu in the reaction mixture. The ⁶⁴Cu-pembrolizumab was purified by SEC-2000 HPLC in PBS buffer [0.1 M NaCl, 0.05 M sodium phosphate (pH 7.4)] at a flow rate of 1 mL/min. The purified tracer was collected at 8 ± 2 min, corresponding to unmodified pembrolizumab and concentrated to ∼5 mg/mL (by UV 280 nm) using a Vivaspin, 30-kDa cutoff centrifugal filter.

**Quality of ⁶⁴Cu-pembrolizumab: Purity, Immunoreactivity, and Stability.** Radio-thin layer paper chromatography (R-TLC) and SEC. 2000 radio-HPLC were performed to assess the tracer quality. Immunoreactivity and serum stability were carried out as per published methods described elsewhere. The ⁶⁴Cu-pembrolizumab tracer serum stability was assayed with normal human serum (Sigma Aldrich, St Louis, MO) and incubated at 37°C. Briefly, tracer and serum were mixed for 6 h. After 6 h, 100 μL was aliquoted and analyzed by radio-HPLC and the eluent was collected in 1-mL fractions and counted in a gamma counter. Percent activity of each fraction was computed to measure tracer stability in serum. Tracer pyrogenicity and sterility tests were performed as per previously published procedures.

**Animal Studies.** Animal studies were approved by the Administrative Panel on Laboratory Animal Care (APLAC) at Stanford University. NOD.Cg-PrkdcsidIl2rgtm1wjl/SzJ mice (NSG) were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained in-house in an accredited facility. The average weight of the NSG mice was 23.0 ± 4.0 g. Humanized NSG mice (hNSG/A375) were developed as per the methods published elsewhere and utilized for the immunoPET imaging study. Briefly, human peripheral blood mononuclear cells (hPBMCs) were isolated from normal human blood and tested by FACS for the expression of hCD45- and hPD-1-positive lymphocytes. 5 × 10⁶ hPBMCs were injected via tail vein into NSG mice bearing a human A375 melanoma in the left shoulder, to create hNSG/A375 mice. 293 T/hPD-1 cells were xenografted into the left shoulder of NSG mice, to create NSG/293 T/hPD-1 mice. Furthermore, we studied two groups within each mouse model, pre-blocking hPD-1 with non-radioactive pembrolizumab (blk) and not pre-blocking (nblk), to demonstrate the specificity and increased immunoPET tracer hPD-1 targeting in the nblk group. The blk subgroups received a sufficient pre-dose of non-radioactive pembrolizumab (4 mg/kg) to block the majority of hPD-1 receptors. Supplementary Fig. S5 summarizes the four groups evaluated in this study.

Two groups of hNSG/A375 mice (hNSG/A375-blk and hNSG/A375-nblk, n = 4/group), received ⁶⁴Cu-pembrolizumab (200 μL, equivalent of 7.4 ± 0.4 MBq dose, 20–25 μg of DOTA-pembrolizumab) via tail vein injection. After radiotracer administration, microPET-CT imaging was performed on a Siemens Inveon small-animal multimodality PET-CT system (Preclinical Solutions; Siemens Healthcare Molecular Imaging, Knoxville, TN) at the Stanford Small Animal Imaging Center. The PET-CT scanning was performed (microPET default settings with energy window of 350–650 keV) at the following time points after the tracer injection: 1, 2, and 4 h, each for 3-min duration; 18 and 24 h, each for 5-min duration; 24 h for 10-min duration; and 48 h for 15-min duration.
The images acquired from microPET-CT were reconstructed with the two-dimensional ordered-subset expectation maximization (OSEM 2D) algorithm. Regions of interest (ROIs) of selected organs (spleen, heart, liver, tumor, and muscle) were computed using Inveon Research Workspace software (Preclinical Solutions; Siemens Healthcare Molecular Imaging, Knoxville, TN). ROI volume was converted to radioactivity concentration in counts per minute (cpm) by using a predetermined conversion factor. The percent injected dose per gram of tissue (% ID/g) was estimated by dividing the injected dose by the weight of the organ.

**Biodistribution Study of \(^{64}\)Cu-pembrolizumab.** Two groups of NSG/293 T/hPD-1 mice (n = 3 blk, and n = 5 nblk) were xenografted with hPD-1—expressing 293 T cells. Each mouse was implanted with 2 × 10^6 cells in a volume of 100 μL of single-cell suspension containing Matrigel/293 T/hPD-1 in the left shoulder. For the NSG/293 T/hPD-1 mice, the subcutaneous tumor height (h), width (w), and length (l) were measured by caliper, and the volume was estimated as an ellipsoid using the formula \( V = \frac{\pi}{6}h \cdot w \cdot l \); for the hNSG/A375 mice, the height was estimated as \( h = \frac{l^2}{2} / 3 \) and the volume was calculated per the aforementioned formula \(^{14}\). Mice with 293 T or A375 engraftment volumes ranging from 300–400 mm^3 were used for the imaging and biodistribution studies. The \(^{64}\)Cu—pembrolizumab tracer (200 μL, corresponding to 7.4 ± 0.4 MBq, 20–25 μg) was administered in all four groups of mice (NSG/293 T/hPD-1-blk, NSG/293 T/hPD-1-nblk, hNSG/A375-blk, and hNSG/A375-nblk), which were sacrificed 48 h after the microPET-CT scan. Animals were euthanized by CO\(_2\) gas asphyxiation for in vivo biodistribution studies. Ex vivo biodistribution studies were performed separately using the hNSG/A375-blk and hNSG/A375-nblk groups (n = 3–4/group), at four different time points (1, 12, 24, and 48 hours p.i.), and the mice were sacrificed to excise the organs to predict human dosimetry. Organs were removed, rinsed in PBS, dried in air for 5 min, and weighed and counted in a gamma-counter to determine corresponding radioactivity. The immunoPET tracer dose uptake by each organ was determined by measuring the total number of cpm. Count data were background-subtracted and decay-corrected to the time of injection, and the % ID/g for each tissue sample was calculated.

**Histology and Immunofluorescence.** 24 hours post-injection of tracer in additional NSG/293 T/hPD-1 mice (blk and nblk), the animals were sacrificed. The left-sided subcutaneous tumor and right-sided normal tissue (control) were excised and placed separately in 10% formalin at 4 °C. Two days prior to tissue sectioning, the tissues were placed in 30% (w/v) sucrose in PBS for cryopreservation. On the day of tissue sectioning, the tissues were placed in optimum cutting temperature (OCT, Fisher Scientific, Waltham, MA) compound and frozen to −20 °C. Using a microtome, tissues were cut into 10 μm-thick sections (for immunofluorescence staining) or 25 μm-thick sections (for routine hematoxylin and eosin [H&E] staining), and the sections were mounted to frosted microscope slides and stored at −80 °C.

Tissue slides were removed from the −80 °C freezer and allowed to equilibrate to room temperature over 20 minutes. The tissues were blocked for 1.5 hours in 10% (v/v) fetal bovine serum and 1% (v/v) DMSO in PBS. The blocking solution was then removed. Alexa Fluor® 488 anti-human CD279 (PD-1) antibody (catalog# 329936, Biolegend, San Diego, CA) was used to detect the tumor tissue and DyLight® 594 Goat Anti-Human IgG Fc (catalog# ab97005, Abcam, Cambridge, MA) was used to detect pembrolizumab. After testing serial dilutions of the antibodies, the optimal dilutions were used. The antibodies were diluted in 10% fetal bovine serum (v/v) in PBS, applied to the tissue, shielded from light, and incubated overnight at 4 °C. The next day, the slides were washed three times with PBS. Cover slips were mounted using VECTASHIELD Antifade Mounting Medium with DAPI (catalog# H-1200, Vector Laboratories, Burlingame, CA). The edges of the cover slip were sealed with clear nail polish. Images (40× zoom) were acquired using a NanoZoomer 2.0-RS whole slide imager (Hamamatsu, Hamamatsu City, Japan) and saved as TIFF files using the NanoZoomer Digital Pathology (NDP) Scan version 2.5 software.

**Dosimetry.** The human equivalent dose was calculated from the injected dose activity of each animal organ using the method of Kirschner et al. \(^{35}\). The tracer uptake in each mouse’s organ of interest was manually defined with ROIs by Inveon Research Workspace software from PET/CT images acquired 1–48 hours p.i. \(^{64}\)Cu-pembrolizumab uptake was determined in the following organs that are readily demarcated on visual inspection on the PET/CT images: heart, liver, spleen, muscle, and tumor; a final 3D ROI was generated from multiple 2-dimensional images. For ex vivo tissue analysis, 12 organs (blood, heart, lungs, liver, spleen, pancreas, stomach, small intestine, large intestine, kidney, muscle, and tumor) were excised and their cpm’s were determined. The ROI values were derived as % injected dose/gram, and each of these values was subsequently converted to the human equivalent % injected dose/gram for each organ. The residence times for each organ were calculated using trapezoidal integration. The internal radiation dosimetry for each group was evaluated through the normalized cumulative activities that were calculated, and the equivalent residence times for each organ in each mouse group was entered into OLINDA/EXM 1.2 code \(^{44}\). The integral value of time activity per organ (µCi-h/µCi injected) was computed from the human equivalent dose. Human dose estimation was performed with the OLINDA/EXM version 1.2 software (Vanderbilt University, Nashville, TN) \(^{36}\).

**Statistical Analysis.** Unpaired two-tailed Student’s t test was used to compare mean values between groups. A p-value less than 0.05 was considered to be statistically significant. Data are presented as mean ± standard deviation (SD).

**Data Availability.** All methods were performed in accordance with the relevant guidelines and regulations by Stanford University.
References

1. Hamid, O. & Carvajal, R. D. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther 13, 847–861, https://doi.org/10.1517/14712598.2013.770836 (2013).

2. Blank, C. & Mackensen, A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer immunology, immunotherapy: CIIT 56, 739–745, https://doi.org/10.1007/s00262-006-0272-1 (2007).

3. Imai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America 99, 12293–12297, https://doi.org/10.1073/pnas.192461099 (2002).

4. Stecher, C. et al. PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. Front Immunol 8, 572, https://doi.org/10.3389/fimmu.2017.00572 (2017).

5. Chinti, J. M. et al. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 36, 587–595, https://doi.org/10.1016/j.tips.2015.06.005 (2015).

6. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28, 3167–3175, https://doi.org/10.1200/JCO.2009.26.7609 (2010).

7. Fourcade, J. et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. Journal of immunology 182, 5240–5249, https://doi.org/10.4049/jimmunol.0803245 (2009).

8. Patnaik, A. et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 21, 4286–4293, https://doi.org/10.1158/1078-0432.CCR-14-2007 (2015).

9. Shimizu, T. et al. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs 34, 347–354, https://doi.org/10.1007/s10637-016-0347-6 (2016).

10. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England journal of medicine 369, 134–144, https://doi.org/10.1056/NEJMoa1305133 (2013).

11. Francisco, L. M., Sage, P. T. & Sharpe, A. H. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236, 219–242, https://doi.org/10.1111/j.1600-065X.2010.00923.x (2010).

12. Brown, J. A. et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. Journal of immunology 170, 1257–1266 (2003).

13. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8, 793–800, https://doi.org/10.1038/nm730 (2002).

14. Sharpe, A. H. & Freeman, G. J. The B7-CD28 superfamily. Nature reviews. Immunology 2, 116–126, https://doi.org/10.1038/nri7272 (2002).

15. Thompson, R. H. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Journal of immunology 173, 1757–1761, https://doi.org/10.1074/ji.2006.041232 (2007).

16. Nomil, T. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed-death-1 pathway in human pancreatic cancer. Cancer research: an official journal of the American Association for Cancer Research 67, 2151–2157, https://doi.org/10.1158/0008-5472.CAN-06-2746 (2007).

17. Haminashi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 104, 3360–3365, https://doi.org/10.1073/pnas.0611533104 (2007).

18. Natarajan, A., Mayer, A. T., Reeves, R. E., Nagamine, C. M. & Gambhir, S. S. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Mol Imaging Biol, https://doi.org/10.1007/s11307-017-1060-3 (2017).

19. Patel, S. P. & Kurczrock, R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 14, 847–856, https://doi.org/10.1158/1535-7186.MCT-14-0983 (2015).

20. Die, M. et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27, 147–153, https://doi.org/10.1093/annonc/mdv489 (2016).

21. Chen, Y. B., Mu, C. Y. & Huang, J. A. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumors 98, 751–755, https://doi.org/10.1700/1217.13499 (2012).

22. Aflakpas, S. P. et al. In vivo imaging reveals a tumor-associated mesophoge-mediated resistance pathway in anti-PD-1 therapy. Science Transl Med 9, https://doi.org/10.1126/scitranslmed.aal3604 (2017).

23. Engall, C. G. et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-labeled Pembrolizumab. J Nucl Med, https://doi.org/10.2967/jnumed.117.177857 (2016).

24. Witting, T. E. Vitrinum-90 /britumomab tuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barc) 40, 111–119 (2004).

25. Radioactive drugs for certain research uses. Washington DC: National Archives and Records Administration, Office of the Federal Register; Title 21 DFR 361.1 (2011).

26. van Dongen, G. A., Visser, G. W., Lub-de Hooge, M. N., de Vries, E. G. & Perk, L. R. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncol Lett 12, 1379–1389, https://doi.org/10.3892/ol.2012.1379 (2011).

27. McCabe, K. E. & Wu, A. M. Positive progress in immunoPET—not just a coincidence. Cancer Biother Radiopharm 25, 253–261, https://doi.org/10.1089/cbr.2010.0776 (2010).

28. Protection, I. I. C. O. R. Radiation Dose to Patients from Radiopharmaceuticals, Publication 106. Washington DC: National Archives and Records Adiministration, Office of the Federal Register; Title 21 DFR 361.1 (2011).

29. Natarajan, A., Arksey, N., Iagaru, A., Chinn, F. T. & Gambhir, S. S. Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma. Mol Imaging 14, https://doi.org/10.2310/7290.2014.00055 (2015).

30. Suffner, J. et al. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.JucidDTR mice. J immunology 184, 1810–1820, https://doi.org/10.4049/jimmunol.0900240 (2010).

31. Sapi, J. et al. Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy. PLoS One 10, e0142190, https://doi.org/10.1371/journal.pone.0142190 (2015).

32. Kirschner, A. S., Ice, R. D. & Beierwaltes, W. H. Radiation dosimetry of 131I-19-iodocholesterol. J Nucl Med 14, 713–717 (1973).

33. Stabin, M. G. & Siegel, J. A. Physical models and dose factors for use in internal dose assessment. Health Phys 85, 294–310 (2003).
Acknowledgements
We would like to thank The Canary Foundation, The Ben and Catherine Ivy Foundation, and the National Cancer Institute (P50CA114747) for their support and for helping to fund this research. We acknowledge the support of Dr. Timothy Doyle. MicroPET/CT imaging was performed in the Sci3 Stanford Small Animal Imaging Service Center.

Author Contributions
A.N. performed study design, development, methodology, acquisition of data, and wrote the main manuscript text; A.N., F.H., and C.P. prepared Figs 1–5. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-19123-x.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018